Clinical Trial Update: A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating oral 7HP349 (Alintegimod) in combination with ipilimumab, followed by nivolumab monotherapy, in patients with advanced cancers. The Ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Hepatocellular Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Pleural Mesothelioma
• Renal Cell Carcinoma
• Skin Cancer

Drugs mentioned

• Alintegimod (7HP349)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: 7 Hills Pharma, LLC | Conditions: Advanced Cancer, Advanced Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING